These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 32093809)

  • 1. A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
    Luo Q; Pan W; Zhou S; Wang G; Yi H; Zhang L; Yan X; Yuan L; Liu Z; Wang J; Chen H; Qiu M; Yang D; Sun J
    Oncol Res; 2020 Sep; 28(4):331-344. PubMed ID: 32093809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
    Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY
    Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
    Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
    Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG
    Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
    He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.
    Mahadevan D; Morales C; Cooke LS; Manziello A; Mount DW; Persky DO; Fisher RI; Miller TP; Qi W
    PLoS One; 2014; 9(6):e95184. PubMed ID: 24893165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
    Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA
    Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy.
    Pan R; Ruvolo V; Mu H; Leverson JD; Nichols G; Reed JC; Konopleva M; Andreeff M
    Cancer Cell; 2017 Dec; 32(6):748-760.e6. PubMed ID: 29232553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
    Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
    Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
    Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
    Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S
    Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
    Lee JS; Tang SS; Ortiz V; Vo TT; Fruman DA
    Oncotarget; 2015 Nov; 6(34):35202-17. PubMed ID: 26460954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
    Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.
    Ezell SA; Mayo M; Bihani T; Tepsuporn S; Wang S; Passino M; Grosskurth SE; Collins M; Parmentier J; Reimer C; Byth KF
    Oncotarget; 2014 Jul; 5(13):4990-5001. PubMed ID: 24970801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
    Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
    Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
    Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
    Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
    Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
    J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination p53 activation and BCL-x
    Bell HL; Blair HJ; Jepson Gosling SJ; Galler M; Astley D; Moorman AV; Heidenreich O; Veal GJ; van Delft FW; Lunec J; Irving JAE
    Leukemia; 2024 Jun; 38(6):1223-1235. PubMed ID: 38600316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.